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Sims EK, Hatanaka M, Morris DL, Tersey SA, Kono T,
Chaudry ZZ, Day KH, Moss DR, Stull ND, Mirmira RG, Evans-
Molina C. Divergent compensatory responses to high-fat diet be-
tween C57BL6/J and C57BLKS/J inbred mouse strains. Am J Physiol
Endocrinol Metab 305: E1495–E1511, 2013. First published October
29, 2013; doi:10.1152/ajpendo.00366.2013.—Impaired glucose toler-
ance (IGT) and type 2 diabetes (T2DM) are polygenic disorders with
complex pathophysiologies; recapitulating them with mouse models is
challenging. Despite 70% genetic homology, C57BL/6J (BL6) and
C57BLKS/J (BLKS) inbred mouse strains differ in response to diet-
and genetic-induced obesity. We hypothesized these differences
would yield insight into IGT and T2DM susceptibility and response to
pharmacological therapies. To this end, male 8-wk-old BL6 and
BLKS mice were fed normal chow (18% kcal from fat), high-fat diet
(HFD; 42% kcal from fat), or HFD supplemented with the PPAR
agonist pioglitazone (PIO; 140 mg PIO/kg diet) for 16 wk. Assess-
ments of body composition, glucose homeostasis, insulin production,
and energy metabolism, as well as histological analyses of pancreata
were undertaken. BL6 mice gained weight and adiposity in response
to HFD, leading to peripheral insulin resistance that was met with
increased -cell proliferation and insulin production. By contrast,
BLKS mice responded to HFD by restricting food intake and increas-
ing activity. These behavioral responses limited weight gain and
protected against HFD-induced glucose intolerance, which in this
strain was primarily due to -cell dysfunction. PIO treatment did not
affect HFD-induced weight gain in BL6 mice, and decreased visceral
fat mass, whereas in BLKS mice PIO increased total fat mass without
improving visceral fat mass. Differences in these responses to HFD
and effects of PIO reflect divergent human responses to a Western
lifestyle and underscore the careful consideration needed when choos-
ing mouse models of diet-induced obesity and diabetes treatment.
C57BL/6J; C57BLKS/J; diet-induced obesity; pioglitazone; mouse
models of T2DM
GENOMEWIDE ASSOCIATION STUDIES (GWAS) indicate that the vast
majority of impaired glucose tolerance (IGT) and type 2
diabetes mellitus (T2DM) are polygenic and represent a com-
plex interplay between genetic susceptibility, dietary and life-
style choices, and environment (48). The initial treatment of
T2DM typically consists of a combination of antihyperglyce-
mic agents, including metformin, sulfonylureas, PPAR ago-
nists, or thiazolidinediones (TZDs), and incretin-based thera-
pies; however, this approach is associated with high secondary
failure rates, and many patients will ultimately transition to
insulin therapy in order to achieve glycemic targets (45). While
the field of T2DM pharmacogenomics is relatively undevel-
oped compared with other complex diseases, large clinical
studies have revealed important differences in response to
these therapies based on sex, ethnicity, and other genetic
differences (9, 51). Given the heterogeneous nature of IGT and
T2DM susceptibility and treatment response, modeling these
disorders in the laboratory setting using inbred strains of mice
is fraught with inherent challenges.
C57BL/6J (BL6) mice are one of the most widely utilized
inbred strains in biomedical research (1). Many knockout and
transgenic mouse models are bred congenic on the BL6 back-
ground for metabolic analysis, and BL6 mice are typically
selected to model diet-induced obesity (5, 7, 32, 40). The
C57BLKS/J (BLKS) strain inadvertently arose from the BL6
background as a result of genetic contamination. Subsequent
analysis of the BLKS genome demonstrated 70% contribu-
tion from the BL6 mouse, with 20% from the DBA/2J mouse
and 9% from an unidentified source (8, 29). In contrast to the
BL6 strain, BLKS mice have been characterized as relatively
more resistant to diet-induced obesity (39). Interestingly, in the
context of severe insulin resistance conferred by functional
leptin deficiency, BL6 and BLKS mice both initially develop
hyperglycemia (18). However, BL6 mice are able to compen-
sate with increased insulin production, ultimately developing
only glucose intolerance. In contrast, the BLKS strain develops
severe and progressive hyperglycemia with islet atrophy (18).
The mechanistic reasons for these divergent phenotypes are
incompletely understood.
We hypothesized that distinct phenotypic responses to diet-
induced obesity between the BL6 and BLKS parent strains
would yield important insights into variations in diabetes sus-
ceptibility and disease risk. Because clinical trials utilizing ago-
nists of the nuclear hormone receptor peroxisome proliferator-
activated receptor- (PPAR) for diabetes prevention and treat-
ment have identified “responders” and “nonresponders”, we also
sought to analyze differences in response to the TZD drug piogli-
tazone initiated concurrently with high-fat diet (HFD) treatment.
To this end, male BL6 and BLKS mice were fed either normal
chow containing 18% of calories from fat, HFD comprised of
42% of calories from fat to simulate the typical Western diet,
or HFD supplemented with the PPAR agonist pioglitazone
(HFDPIO), for up to 16 wk. Body composition, glucose
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metabolism, -cell function, death, and architecture, and
energy metabolism were analyzed. Our results demonstrate
that underlying genetic differences as well as behavioral
responses between these strains translate into important and
divergent physiological responses to overnutrition and
PPAR agonist therapy. Differences observed between the
BL6 and BLKS strains may reflect divergent responses of
humans to a Western lifestyle and pharmacological therapy
and underscore the careful consideration needed when
choosing mouse models of diet-induced obesity and T2DM
treatment and when broadly extrapolating preclinical results
from one inbred rodent strain to heterogeneous human
populations.
MATERIALS AND METHODS
Animals and metabolic testing. Male BL6 and BLKS mice were
obtained from Jackson Laboratories (Bar Harbor, ME) and maintained
under protocols approved by the Indiana University School of Med-
icine Institutional Animal Care and Use Committee in accord with the
Association for Assessment and Accreditation of Laboratory Animal
Care guidelines. Beginning at 8 wk of age, animals were fed either
normal chow (Harlan-Teklad Global, catalog number 2018S) contain-
ing 18% calories from fat (regular diet), high-fat diet (Harlan-Teklad
Global, catalog no. TD88137) containing 42% calories from fat
(HFD), or high-fat diet compounded by Harlan-Teklad Global with
140 mg/kg pioglitazone (HFDPIO). This ratio of drug to chow was
calculated to provide a dose of 20 mg·kg1·day1 PIO. All mice were
kept on a standard light-dark cycle with ad libitum access to chow and
water. Animals were housed five mice per cage, and food was
changed and measured twice weekly. Analyses were performed by the
same group of three individuals on three separate cohorts of mice.
Intraperitoneal glucose tolerance tests (IPGTTs) were performed
after 10 wk on diet following a 16-h fast and intraperitoneal injection
of 2 g/kg D-glucose solution. Blood was sampled from the tail vein at
0, 10, 20, 30, 60, 90, and 120 min, and glucose was measured using
a glucometer (AlphaTRAK, Abbott Park, IL). Intraperitoneal insulin
tolerance tests (IPITTs) were performed on random fed mice follow-
ing an intraperitoneal injection of 0.75 U/kg Humulin-R insulin (Lilly,
Indianapolis, IN). Blood glucose was measured from tail vein blood at
0, 15, 30, 45, and 60 min. Fasting serum insulin was measured using
an ultrasensitive mouse insulin ELISA (Crystal Chem, Downers
Grove, IL). The homeostasis model of assessment of insulin resistance
(HOMA-IR) was calculated as fasting glucose (mM) fasting insulin
(U/ml)/22.5 (46).
Body composition was measured by dual-energy X-ray absorpti-
ometry (DEXA) after 12 wk of diet, using a Lunar PIXIMus DEXA
Scanner (GE Medical Systems, Fairfield, CT) on mice anesthetized
with inhaled isofluorane. Indirect calorimetry measures were per-
formed after 12 wk of diet using a TSE systems LabMaster Metabo-
lism Research Platform (Chesterfield, MO) equipped with calorime-
ter, feeding, and activity system. All measurements were performed
after a 24-h acclimation period followed by 24 h of data collected
every 10 min. Respiratory quotient (RQ) and energy expenditure (EE)
were calculated as previously described (44), and results are displayed
in terms of mean measurements over a 24-h period as well as during
light (0700–1900) and dark cycles (1900–0700). Percent relative
cumulative frequency (PRCF) curves were generated from RQ values
as previously described (33).
For 10 animals per group, euthanized after 14–15 wk on diet, blood
was obtained by cardiac puncture on random fed mice for measure-
ment of serum insulin and leptin levels, which were assessed using
ELISA assays (Crystal Chem, Downers Grove, IL). To provide an in
vivo measurement of -cell death, multiplex PCR analysis of differ-
entially methylated insulin DNA was performed on terminal serum
collected from five animals per group after 12–13 wk of diet, as
previously described (12).
Epididymal fat was isolated, frozen in liquid nitrogen, and stored at
80°C until analysis. Total RNA was isolated using RNeasy Lipid
Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions, and the optional on-column DNase digestion step was
performed for each sample. cDNA was generated from 1.0 g of total
RNA using M-MLV Reverse Transcriptase and random hexamers
(both from Invitrogen, Life Technologies, Grand Island, NY). qRT-
PCR was performed using SYBR Green (Sigma-Aldrich, St. Louis,
MO) and data were collected using a Mastercycler ep realplex instru-
ment (Eppendorf, Hauppage, NY). PCR primers used for qRT-PCR
were: leptin (forward: 5=-GAGACCCCTGTGTCGGTTC-3=; reverse:
5=-CTGCGTGTGAAATGTCATTG-3=), adiponectin (forward: 5=-
CAGTGGTCTAGGACCCGAGAA-3=; reverse: 5=-AGGGGGAGAT-
GTTCAGCATGT-3=), and acidic ribosomal phosphoprotein (Arbp; for-
ward: 5=-GCAGGCATCCCAGGACATC-3=; reverse: 5=-GCGATA-
CATATAAGCGGCTTCT-3=). Arbp expression was used as the internal
control for data normalization. Samples were assayed in triplicate and
relative expression was determined using the 2CT method.
Immunofluorescence and morphometric analysis. Pancreata from at
least five mice per treatment group were fixed by cardiac perfusion
with 4% paraformaldehyde, paraffin embedded, and sectioned longi-
tudinally at 5-m intervals. Immunohistochemical analysis of insulin
(rabbit anti-human insulin, Santa Cruz, 1:500) was performed as
previously described (14). Immunofluorescence experiments were
performed for insulin (guinea pig anti-porcine, Invitrogen, 1:250),
glucagon (rabbit anti-mouse, Santa Cruz, 1:500), phosphohistone H3
(PH3; rabbit anti-mouse, Millipore, 1:150), and nuclei (diamidino-2-
phylindole, DAPI). Secondary antibodies were goat anti-rabbit anti-
body conjugated to Alexa fluor 488 (Molecular Probes, 1:50) and goat
anti-guinea pig antibody conjugated to Alexa fluor 555 (Molecular
Probes, 1:200). A Zeiss Axio Observer Z1 inverted microscope
equipped with an Orca ER CCD camera (Hamamatsu Photonics,
Hamamatsu City, Japan) was used to acquire digital images of the
entire stained longitudinal pancreatic section. The -cell area of five
sections, each separated by at least 60 m, from at least five animals
in each group, was calculated using Axio-Vision Software (Zeiss,
Thornwood, NY).
To assess proliferation, four pancreatic sections, each separated by
at least 100 m, from at least three mice per group, were immuno-
stained for insulin, PH3, and DAPI, and cells that stained positive for
insulin, PH3, and DAPI were counted using Image J software (36).
Total insulin-positive cells (positive for insulin and DAPI) counted
per animal ranged from 1,961 to 10,565; (mean of 5,110 	 600 SE).
Results were expressed as the percentage of cells positive for all three
stains relative to the total number of insulin-positive cells (2).
Glucose-stimulated insulin secretion. Mouse islets were isolated
from collagenase-perfused pancreata (CIzyme MA; VitaCyte, India-
napolis, IN) and neutral protease (CIzyme BP Protease, VitaCyte) as
previously described (38). Glucose-stimulated insulin secretion
(GSIS) was performed as previously described, using 40 islets per
mouse (15). Briefly, islets were preincubated in SAB buffer with 2.5
mM glucose for 1 h, switched to SAB buffer containing 2.5 mM
glucose for an additional hour, and then 15 mM glucose for another
hour. Supernatants were collected and assayed using a radioimmuno-
metric assay for insulin (Siemens Healthcare Diagnostics, Deerfield,
IL); values were normalized to total protein content of the islet
fraction.
Islet microarray. After 12 wk of diet, islets from four mice per
group were shipped to Miltenyi Biotec (Auburn, CA) on dry ice,
where RNA was isolated and Agilent Whole Mouse Genome Oligo
Microarray was performed (MACS molecular, Miltenyi Biotec, Au-
burn, CA). Differential gene expression candidates were considered
significant if the P value after one-way analysis of variance (with
Tukey posttest) was 
0.05 and average expression between groups
was at least 1.5-fold different. Differentially expressed reporters were
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hierarchically clustered (Euclidean distance, complete linkage). The
data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO Series
accession no. GSE51055 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?accGSE51055) (11). (It is also linked to the online version
of this paper.)
Statistical analysis. Data values are presented as means 	 SE.
One-way analysis of variance (with Tukey posttest) was used for
comparison of results within and between strains. Multiplicity ad-
justed P values were calculated to account for multiple comparisons.
A P value of 
0.05 was taken to indicate the presence of a significant
difference. Prism 6 software (GraphPad, La Jolla, CA) was used for
all statistical analyses, with the exception of those performed by
Miltenyi Bioinformatics in the evaluation of microarray results.
RESULTS
BL6 mice gain more weight and visceral adiposity on HFD
than BLKS mice; PIO decreased visceral adiposity in BL6 mice
and increased total adiposity in BLKS mice. To assess changes
in body composition over time in response to dietary and
pharmacologic intervention, mice were weighed weekly, and
DEXA scans were obtained after 12 wk on diet. No significant
differences existed in body weight or the percentage of total or
visceral fat between strains on regular diet (Fig. 1, E, K, N). In
both strains, weight gain was increased with HFD (Fig. 1,
A–E); however, BL6 mice gained significantly more weight on
HFD than BLKS mice (Fig. 1E). In BLKS mice, the addition
of PIO increased weight gain compared with HFD alone, but
this effect was notably absent in the BL6 strain (Fig. 1, A–E).
Lean mass did not differ within strains, but BL6 mice had
significantly greater lean mass compared with each respective
BLKS comparison group (data not shown).
While BL6 mice accumulated significantly more total fat
mass than BLKS mice fed HFD (Fig. 1H), both strains dem-
onstrated similarly increased percentages of body fat with HFD
treatment compared with the regular diet group (Fig. 1, I–K).
The addition of PIO had differing effects in each strain. In BL6
mice on HFDPIO, fat mass was unchanged compared with
HFD alone (Fig. 1, F, I). In contrast, compared with the HFD
group, BLKS mice on HFDPIO had an increase in total fat
mass, although the percentage of body fat was not significantly
different (Fig. 1, G, J).
Epididymal white adipose tissue (eWAT) was dissected,
weighed, and expressed as a percentage of total body weight in
order to estimate changes in visceral fat content (Fig. 1, L–N).
HFD treatment significantly increased visceral adiposity in
both strains, but comparison between strains revealed that BL6
mice on HFD had significantly more eWAT as a percentage of
body weight than BLKS mice on HFD. Interestingly, the
addition of PIO decreased visceral adiposity in BL6 mice,
whereas this effect was notably absent in BLKS mice. These
data indicate that, compared with BLKS mice, BL6 mice
demonstrated increased body weight accumulation and in-
creased ability to expand the visceral fat depot in response to
HFD. BL6 mice were also more responsive to the effects of
PIO to decrease visceral adiposity.
HFD worsens glucose tolerance in both strains. To assess
changes in glucose tolerance, IPGTTs were performed after 10
wk of dietary intervention. On regular diet, BL6 mice tended to
be less glucose tolerant than their BLKS counterparts (P 
0.08). HFD worsened glucose tolerance in both the BL6 and
BLKS strains (Fig. 2, A–D). The addition of PIO significantly
improved glucose tolerance in HFD-fed BL6 mice. The area
under the curve analysis of the IPGTT for BLKS mice on
HFDPIO was likewise indistinguishable from that of BLKS
mice fed regular diet. Between-strain differences are shown in
Fig. 2E. Compared with BL6 mice, BLKS mice demonstrated
significantly better glucose tolerance following HFD treatment.
BL6 mice have increased insulin resistance irrespective of
diet compared with BLKS mice, and increased insulin produc-
tion on HFD. To determine whether differences in insulin resis-
tance contributed to changes in glucose tolerance, IPITTs were
also performed 10 wk after dietary intervention. Although differ-
ences between diet groups were not significant within strains,
comparison between strains revealed that BLKS mice were more
insulin sensitive than corresponding BL6 mice (Fig. 3, A–E).
HOMA-IR calculations were performed as a surrogate measure-
ment of insulin resistance, and comparison between strains re-
vealed that HOMA-IR was significantly increased in BL6 mice on
HFD but remained stable in BLKS mice across the three treatment
groups (Fig. 3, L–N).
Fasting and fed serum insulin levels were measured to
provide a context for changes in glucose and insulin tolerance.
Serum insulin levels were markedly increased in BL6 mice on
HFD, and this effect was largely normalized by PIO (Fig. 3, F,
I). Interestingly, despite a worsening of glucose tolerance in
BLKS mice, no significant differences in serum insulin levels
were noted in any of the BLKS treatment groups (Fig. 3, G, J).
Compared with the BLKS strain, BL6 mice demonstrated
significant hyperinsulinemia in response to HFD challenge
(Fig. 3, H, K). Together, these data indicate that BL6 mice
were able to increase insulin levels in response to HFD. In
contrast, compensatory hyperinsulinemia was absent in the
BLKS strain. PIO normalized insulin levels in BL6 mice, with
no apparent effect in BLKS mice.
HFD results in altered adipose-derived hormone expression
in BL6 mice. Because HFD significantly increased visceral fat
mass in both strains, we next sought to compare changes in
gene expression within the epididymal fat depot. Quantitative
RT-PCR was performed on epididymal adipose tissue to eval-
uate the relative mRNA expression levels of adiponectin and
leptin. In BL6 mice, adiponectin expression was significantly
decreased in mice on HFD, and this was normalized by the
addition of PIO (Fig. 4A). Interestingly, no significant differ-
ence in adiponectin expression was noted among the BLKS
groups (Fig. 4B). A threefold increase in leptin expression was
observed in the epididymal fat of BL6 mice on HFD, whereas
leptin expression in BL6 mice on HFDPIO was not signifi-
cantly different compared with mice on regular or HFD diet
(Fig. 4D). In contrast, BLKS mice demonstrated no change in
epididymal adipose leptin expression between any treatment
group (Fig. 4E). Comparisons between strains revealed that
BL6 mice fed HFD had significantly higher leptin expression
than BLKS mice (Fig. 4F). Serum leptin levels were also
measured by ELISA after 15 wk of dietary intervention, and,
strikingly, similar patterns were noted. BL6 mice fed HFD
exhibited a dramatic 20-fold increase in serum leptin compared
with regular diet treatment. PIO significantly decreased this
response, but levels were still higher than those found under
regular diet conditions (Fig. 4G). Interestingly, no significant
differences in serum leptin were noted between any of the
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BLKS groups (Fig. 4H). Comparisons between strains revealed
that both BL6 mice on HFD and HFDPIO had significantly
higher serum leptin levels than the BLKS mice in the same
treatment groups (Fig. 4I). In aggregate, these data suggest that
increased total and visceral fat accumulation seen in BL6 mice
on HFD was accompanied by decreased visceral fat adiponec-
tin expression and increased leptin expression and marked
hyperleptinemia. Changes in visceral fat accumulation with
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Fig. 1. High-fat diet (HFD) results in greater weight gain and visceral adiposity, whereas pioglitazone (PIO) improves visceral adiposity in BL6 mice. A and
B: weight gain in C57BL6/J (BL6) and C57BLKS/J (BLKS) mice fed chow containing 18% calories from fat (Regular Diet), HFD (containing 42% calories from
fat), or HFDPIO was measured weekly over a 12-wk period. C–E: body weights after 12 wk on study diet. F–H: DEXA measurements were performed after
12 wk on study diets to measure fat mass; n  10–13 mice per treatment group. I–K: %body fat was calculated based on measured fat mass as %body weight;
n  10–13 mice per treatment group. L–N: visceral fat mass was measured by epididymal white adipose tissue dissection, which was weighed and expressed
as %total body weight after 16 wk on study diets; n 7–10 per group. Results are displayed as means	 SE. *P
 0.05, **P
 0.01, ***P
 0.001, ****P
 0.0001
for indicated comparisons.
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PIO were correlated with either complete or relative normal-
ization of adiponectin and leptin expression in BL6 mice.
Interestingly, despite increased visceral fat accumulation with
HFD, changes in adiponectin and leptin expression were
largely absent in BLKS mice.
BL6 mice demonstrate increased -cell area percentage in
response to HFD, whereas BLKS mice on HFD demonstrate
increased -cell death. Given the worsening in glucose tolerance
but divergent findings with regard to serum insulin levels, we next
sought to define changes in -cell function and architecture. To
assess changes in islet morphometry after dietary intervention,
pancreata were removed after 14 wk of treatment and stained for
insulin and glucagon. There was no change in the expected
murine islet architecture with HFD or HFDPIO treatment in
either strain (Fig. 5, A, B). The -cell area percentage (relative to
total pancreas area) was significantly increased in BL6 mice on
HFD (Fig. 5, C–E), whereas -cell area percentage in animals
on HFDPIO was not statistically different compared with mice
on regular diet. Similar to serum insulin levels, no statistical
difference in -cell area percentage was noted between the BLKS
groups (Fig. 5D).
-Cell proliferation was assessed by costaining pancreata for
insulin and PH3, which marks cells in the G2 and M phases of
mitosis (20). Consistent with the analysis of -cell area per-
centage, BL6 mice on HFD had increased insulin- and PH3-
positive cells, although the significance of this effect was
limited by variability (Fig. 5F). In contrast, PH3-positive
-cells tended to decrease in BLKS mice on HFD (P 0.099),
with significantly fewer cells in BLKS mice on HFDPIO
compared with regular diet (P 
 0.01; Fig. 5G). Between-
strain comparisons yielded no differences in -cell area per-
centage or proliferation (Fig. 5, E, H).
Differential methylation of circulating preproinsulin DNA
was measured to assess -cell death. No differences existed
between BL6 groups on different diets (Fig. 5I). However,
BLKS mice on HFD demonstrated a marked increase in the
serum unmethylation index, reflecting increased -cell death.
This finding was partially reversed by the addition of PIO (Fig.
5J). BLKS mice on HFD had a significantly higher proportion
of circulating unmethylated DNA compared with BL6 mice on
HFD (Fig. 5K).
To assess differences in islet function ex vivo, islets were
isolated and allowed to recover overnight, and GSIS assays
were performed (Fig. 5L). As previously reported, under
regular diet conditions, BLKS islets displayed a more robust
response to high glucose compared with BL6 islets (3).
However, there was a progressive decrease in GSIS of islets
from BLKS mice fed HFD that reached statistical signifi-
cance in the HFDPIO group. This effect of HFD on islet
function was absent among BL6 treatment groups. These
findings are suggestive of HFD induced -cell dysfunction
in BLKS mice.
Islet gene expression is differentially regulated in BL6 and
BLKS mice on HFD and in response to PIO. Microarray using
whole islet RNA was performed after 12 wk of dietary inter-
vention. Normalization and correlation analysis of the data
revealed only minor variability between replicate experiments
and did not identify any clear outliers within groups. Differ-
ential gene expression analysis (displayed in Figs. 6 and 7,
using heat maps and Venn diagrams) revealed 99 genes with
increased expression in islets of BL6 mice on HFD compared
with regular chow that were not increased in islets of BLKS
mice fed HFD (Fig. 6C) and 169 genes that were uniquely
decreased in the BL6 strain by HFD (Fig. 7C). BLKS mice also
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Fig. 2. HFD worsens glucose tolerance in BL6 to a greater degree than BLKS mice, whereas PIO restores glucose tolerance in HFD-treated mice. A and
B: BL6 and BLKS mice fed Regular Diet, HFD, or HFDPIO for 10 wk were fasted overnight and injected intraperitoneally with 2 g/kg glucose. Blood
glucose concentration was measured over the course of 2 h. C–E: corresponding area under curve (AUC) analyses for intraperitoneal glucose toler-
ance tests; n  10 per group. Results are displayed as means 	 SE. *P 
 0.05, **P 
 0.01, ***P 
 0.001, ****P 
 0.0001 for indicated compari-
sons.
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had distinct changes in islet gene expression induced by HFD,
with 146 genes showing a pattern of increased expression that
was absent in BL6HFD islets (Fig. 6C), whereas 161 genes
uniquely decreased by HFD in BLKS mice (Fig. 7C). Interest-
ingly only one gene was identified that was increased in HFD
in both strains; the identity of this gene was unknown. Simi-
larly, only one common gene was decreased in both strains,
and the function of this gene was unknown (Mus musculus
predicted gene 2,569).
Addition of PIO to HFD also had differential effects on islet
gene expression between strains. Of 100 genes increased by
treating BL6 mice with HFD, 31 (31%) were reversed by
treatment with PIO (Fig. 6D) and 33 of 170 (19.4%) genes that
were decreased by treating BL6 mice with HFD were reversed
by treatment with PIO (Fig. 7D). BLKS islets demonstrated
less response to PIO at the level of gene expression, with
reversal of gene expression in 26 of 150 (17.3%) genes in-
creased by HFD (Fig. 6E) and reversal of expression in only 8
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of 162 (4.9%) of genes that were decreased by treatment with
HFD (Fig. 7E).
Important between-strain differences were noted in path-
ways identified as important for -cell function and adaptation,
including genes encoding for proteins that regulate growth,
proliferation, and inflammation. Table 1 summarizes notable
genes that were differentially regulated by HFD in each cate-
gory, and reversal of HFD-induced changes with PIO treatment
are indicated (Table 1). A seminal report from the Attie group
(21) has previously compared gene expression patterns in islet
of diabetes-resistant BL6 and diabetes-susceptible BTBR
strains with ob/ob mutations. Genes in our study that were
noted to have similar patterns of expression compared with the
Attie study are also indicated in Table 1.
BLKS mice show maintained kilocalorie intake on HFD.
Metabolic cages were utilized to measure differences in food
intake between each strain. Intake in grams was monitored
over a 24-h period, and this information was used to calculate
kilocalorie intake. Animals on a regular diet demonstrated a
clear peak of nocturnal intake. Interestingly, both strains on
HFD tended to eat more consistently throughout the monitor-
ing period (Fig. 8, A, B). Monitoring revealed no differences in
grams of food consumed by BL6 mice on different diets (Fig.
8C). In contrast, BLKS mice on HFD ate significantly fewer
grams of food compared with BLKS mice on regular chow
(Fig. 6D). In terms of caloric intake, these differences trans-
lated to a significant increase in kilocalories consumed by BL6
mice on HFD and HFDPIO (Fig. 8E). In contrast, kilocalorie
consumption was stable in BLKS mice fed regular diet or HFD
(Fig. 8F).
BLKS mice demonstrate increased activity on HFD. Indirect
calorimetry was used to analyze differences in activity by record-
ing the number of beam breaks occurring in the xy- and z-axes.
As shown in Fig. 9, A–C, measurements differed between strains
and within groups. Compared with regular diet, the average
number of beam breaks was significantly decreased in BL6 mice
on HFD. The addition of PIO to HFD partially restored activity to
the level observed in the regular chow group (Fig. 9A). These
patterns persisted through both light and dark cycles of the 24-h
monitoring period (Fig. 9, D, G). Conversely, BLKS mice on
HFD demonstrated a significant increase in movement counts
throughout the 24-h period (Fig. 9B). BLKS mice on HFDPIO
also had increased activity during the dark cycle compared with
mice on regular chow (Fig. 9H), but the differences were not
significant during the light cycle (Fig. 9E). Strikingly, comparison
between strains revealed that BL6 mice demonstrated increased
beam breaks recorded compared with BLKS mice under regular
diet conditions. However, a complete reversal of this pattern was
noted with HFD, where BLKS mice manifested significantly
increased activity compared with the BL6 mice fed HFD (Fig. 9,
C, F, I).
BLKS mice demonstrate increased RQ values. RQ values
were calculated to provide insight regarding fuel utilization. As
expected, RQ values were significantly decreased over the
entire time period for both strains on HFD compared with
regular diet, and this difference was most pronounced during
the dark cycle (Figs. 7, A, B, and 10, A, B). The addition of PIO
to HFD increased the RQ during the dark cycle for BL6 mice
and increased the RQ during the light cycle for BLKS mice
(Fig. 10, F, D). Differences between strains were most pro-
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Fig. 4. Changes in adiponectin and leptin expression and serum leptin levels were more pronounced in BL6 mice fed HFD and partially normalized with PIO.
Adiponectin (A–C) and leptin gene expression (D–F) were measured in epididymal white adipose tissue by qRT-PCR in BL6 and BLKS mice fed regular Diet,
HFD, or HFDPIO for 16 wk. G–I: random-fed serum was collected after 16 wk on diet, and leptin levels were quantitated using ELISA; n  7–10 mice per
treatment group. Results are displayed as means 	 SE. *P 
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 0.0001 for indicated comparisons.
E1501RESPONSE TO DIET-INDUCED OBESITY IN INBRED MOUSE STRAINS
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00366.2013 • www.ajpendo.org
 by 10.220.32.247 on Decem
ber 22, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
AInsulin/Glucagon/Dapi Insulin/Glucagon/Dapi
100 μm
Regular Diet HFD HFD + PIO
0.0
0.5
1.0
1.5
Pe
rc
en
ta
ge
 C
el
l A
re
a
β β β
β β β
*
Regular Diet HFD HFD + PIO
0.0
0.5
1.0
1.5
Pe
rc
en
ta
ge
 C
el
l A
re
a
Pe
rc
en
ta
ge
 P
H
3
Po
si
tiv
e 
 C
el
ls
Regular Diet HFD HFD + PIO
0.0
0.1
0.2
0.3
0.4
0.5
Pe
rc
en
ta
ge
 P
H
3
Po
si
tiv
e 
 C
el
ls
Regular Diet HFD HFD + PIO
0.0
0.1
0.2
0.3
0.4 **
Pe
rc
en
ta
ge
 P
H
3
Po
si
tiv
e 
 C
el
ls
Regular Diet HFD HFD + PIO
0.0
0.1
0.2
0.3
0.4
0.5
BL6
BLKS
Regular Diet HFD HFD+PIO
0.00
0.05
0.10
0.15
0.20
0.25
U
nm
et
hy
la
tio
n 
In
de
x
U
nm
et
hy
la
tio
n 
In
de
x
Regular Diet HFD HFD+PIO
0.00
0.05
0.10
0.15
0.20
0.25 ** *
Regular Diet HFD HFD + PIO
0.00
0.05
0.10
0.15
0.20
0.25
U
nm
et
hy
la
tio
n 
In
de
x
BL6
****
BLKS
Pe
rc
en
ta
ge
 C
el
l A
re
a
Regular Diet HFD HFD + PIO
0.0
0.5
1.0
1.5
BL6
BLKS
B
DC E
GF H
JI K
L
REG HFD HFD
+PIO
REG HFD HFD
+PIO
0
1000
2000
3000
4000
5000
In
su
lin
 R
el
ea
se
(µ
un
it/
 m
g 
pr
ot
ei
n)
BL6 BLKS
***
**
Low Glucose
High Glucose
Fig. 5. BL6 mice demonstrate increased -cell area in response to HFD, whereas BLKS mice show increased -cell death. A and B: immunofluorescent staining
of insulin and glucagon was performed on pancreatic sections from BL6 and BLKS mice fed Regular Diet, HFD, or HFDPIO for 16 wk. C–E: -cell area was
quantitated; n  5–6 mice per treatment group. F–H: nos. of phosphohistone H3 (PH3)- and insulin-positive cells/total insulin positive cells were quantitated
in each group. Scale bars, 100 m; n  3–4 mice per treatment group. I–K: unmethylation index of preproinsulin DNA was calculated as a measure of -cell
death based on RT-PCR of serum after 12–13 wk on diet; n  5 mice per treatment group. L: glucose-stimulated insulin secretion (GSIS) was performed in
isolated islets from 6 mice in each treatment group. Secreted insulin was normalized to total protein content of islet fraction; n  4 mice per treatment group.
Results are displayed as means 	 SE. *P 
 0.05, **P 
 0.01, ***P 
 0.001, ****P 
 0.0001 for indicated comparisons.
E1502 RESPONSE TO DIET-INDUCED OBESITY IN INBRED MOUSE STRAINS
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00366.2013 • www.ajpendo.org
 by 10.220.32.247 on Decem
ber 22, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
nounced during the dark cycle, with BLKS mice having higher
mean RQ values for regular diet, HFD and HFDPIO com-
pared with BL6 mice in the same groups (Fig. 10H). During the
light cycle, only BLKS mice in the HFDPIO group had a
higher RQ than the corresponding BL6 mice (Fig. 10E).
Percent relative cumulative frequency (PRCF) curves were
generated from 24-h RQ data as previously described to quan-
titate differences in relative metabolic flexibility or capability
to alternate between different fuel substrates as an energy
source (Fig. 10, I–M) (34). For both strains of mice, the PRCF
hill slope significantly increased with HFD (Fig. 10, K–M),
indicating decreased metabolic flexibility with HFD treatment.
Interestingly, PIO further increased the hill slope compared
with HFD alone in BL6 mice but did not alter the slope in
BLKS mice. BLKS mice tended to have more metabolic
flexibility across treatment groups, with a significant difference
in slope for animals on HFD and HFDPIO. Together, these
findings suggest that BL6 mice have impaired metabolic flex-
ibility compared with BLKS mice, which is exacerbated by
HFD and further worsened by PIO.
BLKS mice have increased calculated EE. Finally, EE was
calculated according to the following formula: EE  [3.815 
1.232  RQ]  V˙ O2  0.001 [kcal/(kgxh)]. Total calculated EE
decreased in BLKS mice on HFD compared with regular diet but
was unchanged between these groups in BL6 mice (Fig. 11, A, B,
D, E). Interestingly, the addition of PIO to HFD increased EE in
both strains, although this difference was more pronounced in
BL6 mice (Fig. 11, A, B, D, E). BLKS mice on regular diet and
HFD alone had significantly greater EE than BL6 mice in corre-
sponding groups throughout the monitoring period (Fig. 11, C, F).
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Fig. 6. Islet gene expression upregulated by HFD differs between BL6 and BLKS strains. RNA isolated from islets of BL6 and BLKS mice fed Regular
Diet, HFD, or HFDPIO for 12 wk was analyzed using Agilent Whole Mouse Genome Oligo Microarray. Differential gene expression in BL6 groups
(A) and BLKS groups (B) for genes increased by HFD is depicted using a heat map. Venn diagrams depict overlap in genes (C) with increased expression
in BL6 and BLKS mice on HFD, and reversal of HFD-induced increases in gene expression with PIO treatment in BL6 (D) and BLKS (E) mice; n 
4 mice per treatment group.
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DISCUSSION
The goal of our study was to define the unique compensatory
mechanisms through which BL6 and BLKS mice respond to
HFD treatment and to characterize differences in strain re-
sponses to PIO treatment initiated concurrently with HFD.
While neither strain progressed to frank diabetes during the
study, treatment with chow containing 42% of calories from fat
led to diet-induced obesity and impaired glucose tolerance and
offered an opportunity to phenotype body composition, glu-
cose metabolism, -cell function and architecture, and energy
metabolism in these two commonly used inbred strains of
mice.
Analysis of these two particular strains was undertaken for
several reasons. First, they are genetically related and share
70% overlap in their genome. Therefore, phenotypic differ-
ences may form the foundation for studies to uncover key
modifier genes. Second, the responses of these strains differ
significantly in the setting of functional leptin deficiency
(ob/ob and db/db mice), where both strains are polyphagic and
initially hyperglycemic. Interestingly, the BL6 mouse is able to
compensate with increased insulin production and develops
only glucose intolerance, whereas the BLKS strain develops
severe and progressive hyperglycemia with islet atrophy (18).
In the context of the two parent background strains, the
mechanistic reasons for these divergent phenotypes are incom-
pletely understood. Finally, many knockout and transgenic
strains are bred congenic on the BL6 strain, and we sought to
define how broadly applicable the BL6 response might be to
divergent human populations.
Our results show that BL6 mice consumed consistent grams
of food but more kilocalories when challenged with HFD.
They responded to increased weight and visceral fat accumu-
lation with hyperinsulinemia and hyperleptinemia and had
increased visceral fat leptin gene expression and decreased
C.
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Fig. 7. Islet gene expression decreased by HFD is differentially regulated between BL6 and BLKS strains. RNA isolated from islets of BL6 and BLKS mice fed
Regular Diet, HFD, or HFDPIO for 12 wk was analyzed using Agilent Whole Mouse Genome Oligo Microarray. Differential gene expression in BL6 groups
(A) and BLKS groups (B) for genes decreased by HFD is depicted using a heat map. Venn diagrams depict overlap in genes (C) with decreased expression in
BL6 and BLKS mice on HFD, and reversal of HFD-induced decreases in gene expression with PIO treatment in BL6 (D) and BLKS (E) mice; n  4 mice per
treatment group.
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adiponectin expression. In contrast, BLKS mice, which were
more insulin sensitive at baseline, responded to the challenge
of HFD by restricting food intake and increasing movement,
ultimately limiting weight gain and protecting themselves from
the same degree of metabolic dysfunction encountered by BL6
mice. Notably absent in the BLKS response was any increase
in -cell area or proliferation or insulin output. To the contrary,
BLKS mice on HFD showed a striking increase in serum
unmethylated insulin DNA, reflecting -cell death in response
to HFD.
The metabolism field frequently utilizes knockout and trans-
genic models bred congenic on the BL6 background for anal-
ysis. Although the need for consistency in background within
a cohort is appreciated in order to adequately interpret exper-
imental findings, our study suggests that variance from the use
of a BL6 background strain may be informative in certain
situations. For example, certain Asian and Native American
populations are predisposed to T2DM at younger ages and
lower body mass index (BMI) values compared with Cauca-
sians and manifest more pronounced alterations in -cell func-
tion (4, 6, 23). This susceptibility to glucose intolerance mir-
rors that of BLKS mice. Asian populations are also predis-
posed to development of metabolic syndrome at lower BMI
values compared with other ethnic backgrounds (28). This
predisposition parallels the vulnerability of BLKS mice to
visceral fat accumulation on HFD despite decreased intake and
overall weight gain. Interestingly, BLKS mice on HFD have
previously been noted to have increased development of ath-
erosclerosis compared with BL6 mice (30).
BLKS mice responded to increased chow energy density by
limiting intake and increasing activity, mirroring individuals
who maintain normal weight despite the modern obesogenic
environment. Similar to mice in our study, predisposition to
increased activity thermogenesis appears to be largely deter-
mined by genetics (19). In lean individuals who are challenged
with chronic overfeeding, resistance to obesity was directly
predicted by spontaneous increases in activity (25). Con-
versely, BL6 mice, which consumed significantly more kilo-
calories per day when offered an energy-dense diet, may
provide a more appropriate model for obese individuals with
similar maladaptive responses, which are amplified by pro-
longed exposure to the typical modern environment of excess
calories and reduced need for movement (10, 37). Similarly to
the BL6 strain, exposure of many humans to this environment
translates to increased energy intake and decreased planned
and spontaneous activity, ultimately leading to obesity in
individuals without any inherent self-regulation to keep the
process in check. (17, 26). Given these findings, the BL6 strain
would be particularly advantageous when studying genes that
might modify the development of feeding behavior or adipos-
ity.
Because GWAS studies point to underlying -cell suscep-
tibility as the most consistently identified genetic risk factor for
T2DM, we carefully analyzed the -cell phenotype of both
Table 1. Differentially expressed genes in BL6 and BLKS islets after 12 wk of HFD
Gene Probe Category Description
Increased in BL6 mice on HFD
Ccne1* A_51_P408946 Cell cycle/growth/proliferation Cyclin E1
Cdkn2a* A_55_P2008437 Cell cycle/growth/proliferation Cyclin-dependent kinase inhibitor 2A, transcript variant 1
Cdkn2c* A_55_P2074796 Cell cycle/growth/proliferation Cyclin-dependent kinase inhibitor 2C (p18, inhibits
CDK4)
Gas2l3* A_55_P2064676 Cell cycle/growth/proliferation Growth arrest-specific 2 like 3
Cdkn1a# A_51_P363947 Cell cycle/growth/proliferation Cyclin-dependent kinase inhibitor 1A (P21), transcript
variant 1
Rgs16 A_51_P249286 Cell cycle/growth/proliferation Regulator of G-protein signaling 16
Sh2d1b1 A_51_P496540 Insulin signaling and growth adaptation SH2 domain protein 1B1
Rab39* A_51_P351217 Member of RAS oncogene family,
Membrane trafficking
RAB39, member RAS oncogene family
Decreased in BL6 mice on HFD
Cdk12# A_55_P1999187 Cell cycle/growth/proliferation Cyclin-dependent kinase 12, transcript variant 3
Jun A_55_P2158990 Cell cycle/growth/proliferation Jun oncogene
Fosb A_55_P2113051 Cell cycle/growth/proliferation FBJ osteosarcoma oncogene B
Igf2bp2# A_55_P2170737 Cell cycle/growth/proliferation Insulin-like growth factor 2 mRNA binding protein 2
Grb10 A_55_P1955457 Cell cycle/growth/proliferation Growth factor receptor bound protein 10
Egr1 A_51_P367866 Cell cycle/growth/proliferation Early growth response 2
Btg1 A_55_P2181191 Cell cycle/growth/proliferation B-cell translocation gene 1, anti-proliferative
Errfi1 A_55_P2016105 Cell cycle/growth/proliferation ERBB receptor feedback inhibitor 1
Tgfb2 A_51_P317640 Inflammation/inflammatory response Transforming growth factor, beta 2
Cabin1 A_52_P93422 Calcineurin signal transduction Calcineurin binding protein 1
ENSMUST00000023526 A_55_P2105983 Insulin secretion Syntaxin binding protein 5-like
Increased in BLKS mice on HFD
Il1a A_52_P100926 Inflammation/inflammatory response Interleukin 1 alpha
CxCl5 A_55_P1990032 Inflammation/inflammatory response Chemokine (C-X-X motif) ligand 5
Hpgds A_52_P536796 Inflammation/inflammatory response Hematopoietic prostaglandin D synthase
Decreased in BLKS mice on HFD
Gadd45 g A_51_P315904 Cell cycle/growth/proliferation Growth arrest and DNA-damage-inducible 45 gamma
Cdk15 A_55_P2043734 Cell cycle/growth/proliferation Cyclin-dependent kinase-like 5
Nrg4 A_55_P2185905 Cell cycle/growth/proliferation Neuregulin 4
Nfil3 A_55_P2035320 Inflammation/inflammatory response Nuclear factor, interleukin 3, regulated
BL6, C57BL6/J; BLKS, C57BLKS/J. *Similar pattern of differential regulation in database comparing ob/ob BL6 and BTBR mice. #Reversed by treatment
with pioglitazone.
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strains in response to HFD (13). The absence of major identi-
fied defects in -cell function assessed by GSIS likely reflects
our choice of a more moderate HFD (42% of calories from fat).
This is in contrast to other studies utilizing diets with 60% of
calories from fat, in which abnormalities in GSIS were iden-
tified (31, 49). An important and unique compensatory re-
sponse of the BL6 strain challenged with HFD was to increase
-cell area and proliferation with the parallel development of
significant hyperinsulinemia, consistent with previous studies
demonstrating the high proliferative capacity of BL6 islets
compared with BLKS mice (24, 42). This strain’s ability to
compensate at the -cell level is notable, especially given the
mutation in the Nnt gene. The Nnt mutation developed in the
Jackson Lab C57BL6/J strain and has been reported to affect
insulin secretion and may likely contribute to baseline differ-
ences in glucose tolerance seen between strains on regular diet
(43). However, our findings may also imply a higher threshold
for the development of a dysfunctional phenotype for -cell
gene knockout studies performed in the BL6 strain. Interest-
ingly, no increase in serum insulin or the percentage of -cell
area or proliferation was noted in the BLKS cohort. To the
contrary, despite less weight gain, BLKS mice on HFD have
increased -cell death and similar worsening in glucose toler-
ance compared with BL6 mice. This -cell dysfunction in
response to the stress of mild diet-induced obesity and in-
creased visceral fat accumulation recapitulates the decompen-
sation experienced by this strain on the db/db and ob/ob
backgrounds (18). Intriguingly, with an intact leptin signaling
system, the BLKS strain is able to compensate for the effects
of HFD by limiting weight gain through restoration of energy
balance with decreased kilocalorie consumption that is com-
plemented by increased activity. A similar response to leptin
signaling appears to be absent in BL6 mice, which continue to
generate a positive energy balance on HFD, accumulating
larger amounts of body fat, with apparent increased leptin
resistance and significantly elevated serum leptin levels. The
dependency of the BLKS strain to rely on decreased food
intake to maintain metabolic homeostasis may also provide
additional insight into why these animals rapidly decompensate
when leptin signaling and this “brake” on appetite is impaired
in the db/db and ob/ob backgrounds.
Because of the distinct -cell phenotype observed between
strains, we utilized a microarray to study changes in islet gene
expression as a function of background strain and dietary and
drug intervention. We found that a variety of genes were
differentially expressed between strains and treatment groups.
Several genes known to encode proteins that regulate cell cycle
and growth were found to be different between BL6 and BLKS
mice in response to HFD. A seminal report from the Attie
group has previously compared the diabetes-resistant BL6 and
diabetes-susceptible BTBR strains with ob/ob mutations (21).
Genes with similar patterns of expression in diabetes-resistant
BL6 ob/ob mice and BL6 mice treated with HFD in our study
relative to the comparator diabetes-susceptible strain included
cyclin E1, cyclin-dependent kinase inhibitor 2a, cyclin-depen-
dent kinase inhibitor 2c, growth arrest specific 2-like 3, and the
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Fig. 8. BLKS mice demonstrate consistent kcal
intake on HFD, whereas BL6 mice exhibit sig-
nificantly increased kcal intake on HFD, and
PIO does not affect feeding behavior in BL6
mice. A and B: 24-h intake (g) during light
(0700–1900) and dark cycles (1900–0700) was
calculated. C and D: cumulative intake (g) dur-
ing monitoring period for BL6 and BLKS mice.
E and F: cumulative kcal intake during monitor-
ing period was calculated. Results are displayed
as means 	 SE; n  6–8 per treatment group,
except BLKS mice on HFDPIO, where n 2.
This group exhibited “shredding” behavior of
chow without subsequent consumption, affect-
ing accuracy of measurement. Results are dis-
played for all groups, but BLKS HFDPIO
mice were subsequently excluded from statisti-
cal analysis of intake because shredding behav-
ior required exclusion of a majority of animals
studied. Results are displayed as means	 SEM;
n  8 per treatment group. *P 
 0.05, **P 

0.01, ***P 
 0.001, ****P 
 0.0001 for indi-
cated comparisons.
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member of the Ras oncogene family Rab39. Activation of
growth-regulating pathways is consistent with changes in
-cell area and proliferation seen in the BL6 strain.
BLKS islets exposed to high glucose ex vivo have been
demonstrated to express increased inflammatory response
genes (3). Of note, our microarray data showed increased
expression of a number of these pro-inflammatory genes in
islets from BLKS mice in all treatment groups compared with
BL6 animals. Furthermore, expression of several pro-inflam-
matory genes like IL-1 and CXCL5 increased with HFD.
Interestingly, IL-1 and CXCL5 have previously been linked
to hyperglycemia and diabetes susceptibility in humans (16,
27). These changes suggest a hyperactive inflammatory re-
sponse pathway and could explain, at least in part, the -cell
dysfunction in BLKS animals treated with HFD.
In aggregate, our microarray data suggest that differences in
islet gene expression may contribute to important aspects of the
phenotypic differences observed between the BL6 and BLKS
strains. It is noteworthy that, despite 70% homology, gene
expression changes in response to HFD with or without PIO
were quite distinct between the two strains, with virtually no
overlap in gene expression profiles noted between strains. The
relevance of changes observed in BL6 and BLKS islets will
need to be more fully explored in future studies. For example,
it is interesting to note that nearly equal numbers of positive
and negative regulators of the cell cycle are represented in BL6
islets from HFD-treated mice, clearly suggesting the need for
studies that investigate changes in protein expression and
posttranslational modification as well as alterations in nuclear
and cytoplasmic localization for cell proteins that regulate
growth and proliferation. However, here we provide the full
microarray data for additional hypothesis generation and to
serve as a resource to the community.
BL6 and BLKS mice fed HFD also exhibited distinct re-
sponses to PPAR agonist therapy. Notably, islet microarray
revealed that PIO treatment reversed changes in gene expres-
sion in 24% of differentially regulated genes in BL6 mice on
HFD vs. 11% of differentially regulated genes in BLKS mice
on HFD. The decrease in reversal of HFD-induced gene
expression in BLKS islets could be related to decreased weight
gain and insulin resistance in this group, which could limit
affected genes that could be improved by treatment with PIO.
However, similar numbers of genes were differentially ex-
pressed in islets of BL6 and BLKS mice on HFD, which would
suggest that the decreased response of BLKS islets reflects a
decreased sensitivity to the drug’s effects.
Phenotypic differences in the response to PIO were also
noted. Treatment with PIO improved glucose tolerance and
decreased visceral fat as a percentage of total weight in BL6
mice but had no effect on visceral fat in BLKS mice. BLKS
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Fig. 9. BLKS mice demonstrate increased movement in response to HFD. BL6 and BLKS mice fed Regular Diet, HFD, or HFDPIO for 12 wk were singly
housed in a PhenoMaster LabMaster indirect calorimeter and activity was assessed by recording the number of beam breaks occurring in the xy- and z-axes.
A–C: hourly beam breaks during light (0700–1900) and dark cycles (1900–0700) were recorded over a 24-h period. Average number of beam breaks during
light (D–F) and dark cycle (G–I) in each treatment group. Results are displayed as means 	 SE; n  8 per treatment group. *P 
 0.05, **P 
 0.01, ***P 

0.001, ****P 
 0.0001 for indicated comparisons.
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Fig. 10. BLKS mice demonstrate increased respiratory quotient (RQ) values. BL6 and BLKS mice fed Regular Diet, HFD, or HFDPIO for 12 wk were singly
housed in a PhenoMaster LabMaster indirect calorimeter and RQs were calculated. A and B: hourly RQ values during light (0700–1900) and dark cycles
(1900–0700) were obtained over a 24-h period. C–E: average RQ values during the light cycle were calculated. F–H: average RQ values during the dark cycle.
I–J: percent relative cumulative frequency (PRCF) curves were generated using RQ values over a 24-h period. K–M: Hill slopes of PRCF curves were compared
as a measure of metabolic flexibility. Results are displayed as means 	 SE; n  8 per treatment group. *P 
 0.05, **P 
 0.01, ***P 
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for indicated comparisons.
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mice on PIO had an increase in total body weight, whereas
BL6 mice had stable body weight. In BL6 mice, the addition of
PIO increased the RQ, with a steeper PRCF curve reflecting
decreased metabolic flexibility (33). PIO treatment also in-
creased EE in both strains studied. In contrast, a single dose of
PIO has previously been reported to decrease EE acutely in
rats; however, no changes in RQ values or locomotor activity
were seen between treated and control animals (22). Our
results could have been affected by differences in activity seen
in HFDPIO mice. Alternatively, the increase in RQ and EE
and worsened metabolic flexibility may represent effects of
chronic PIO administration or unique responses of these strains
to PIO. The improved metabolic flexibility noted in BLKS
mice could be a result of enhanced mitochondrial function, as
differences in expression of uncoupling proteins and Nnt have
been previously reported between these strains (3, 41).
Activation of hypothalamic PPAR is known to increase
food intake in rats, resulting in a positive energy balance, and
to contribute to weight gain caused by treatment with the
PPAR agonist rosiglitazone (35). Interestingly, BL6 mice in
our study did not increase food consumption on PIO, suggest-
ing this response may also be affected by genetic background
or may alternatively differ between TZD drugs. Consumption
of BLKS mice on HFDPIO was difficult to interpret, because
this group was excluded from analysis due to shredding be-
havior, which did not allow us to accurately calculate food
intake in this one group. Nevertheless, differing metabolic
responses to PIO between our strains and between published
studies in rats likely reflect variations in the range of effects of
PPAR agonists existing between groups of humans, with
30–40% of participants in large-scale clinical trials demon-
strating heterogeneity or lack of response to effects of TZDs (9,
47). Notably, human genetic variations in the sequence of the
PPAR locus have been associated with response to TZD
treatment (50).
In conclusion, evaluation of the compensatory responses of
BL6 and BLKS mouse strains to diet-induced obesity and
PPAR agonist treatment initiated concurrently with HFD
revealed important physiological and phenotypic differences.
Such variations should be taken into account when designing
studies utilizing either of these two models as representative
human responses to an obesogenic environment, compensation
to HFD, or pharmacological therapies. Finally, our analysis
also suggests that strains other than BL6 may have particular
utility when extrapolating results to a specific human popula-
tion or when investigating a specific component of diabetes
pathophysiology. Differences in effects of PIO on islet gene
expression between strains are especially notable given the
expanding field of diabetes pharmacogenomics and known
differences in response to TZDs between human populations.
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